Worth reading
32Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
Dissolution and liquidation of a consolidated subsidiaryDisclosing companyPhoenixBio Co.,Ltd.
Date of board resolution14 August 2026
Execution Date / Effective DateThe dissolution date, liquidation completion date and other relevant dates have not been determined.
Target company
Management of a consortium for validating the usefulness of PXB mice
Location Delaware, United StatesShare capital US＄250,000Date of incorporation January 2016
Net assets$37,651.61 (fiscal year ending March 2026, USD)
Impact on Business Performance
The Company expects to transfer the foreign currency translation adjustment and incur liquidation-related expenses, but the impact on consolidated results is expected to be immaterial.
Procedures and assumptions
Conditions Precedent to ExecutionThe necessary procedures under Delaware law are scheduled to be carried out.
Management structure after acquisitionDissolution and liquidation are planned. There is no applicable representative. The company has no employees or offices.
| Item | Details |
|---|---|
| Transaction name | Dissolution and liquidation of a consolidated subsidiary |
| Name of the Subject Company | CMHL Consortium LLC. |
| Business Description of the Subject Company | Management of a consortium for validating the usefulness of PXB mice |
| Location of the Subject Company | Delaware, United States |
| Capital Stock of the Subject Company | US＄250,000 |
| Date of Establishment of the Subject Company | January 2016 |
| Net Assets of the Subject Company | $37,651.61 (fiscal year ending March 2026, USD) |
| Voting rights ownership percentage | Before 100% (after not disclosed) |
| Impact on Business Performance | The Company expects to transfer the foreign currency translation adjustment and incur liquidation-related expenses, but the impact on consolidated results is expected to be immaterial. |
| Date of board resolution | 14 August 2026 |
| Execution Date / Effective Date | The dissolution date, liquidation completion date and other relevant dates have not been determined. |
| Conditions Precedent to Execution | The necessary procedures under Delaware law are scheduled to be carried out. |
| Management structure after acquisition | Dissolution and liquidation are planned. There is no applicable representative. The company has no employees or offices. |
Items this document does not state (19)
Counterparty nameNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Contract DateValuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The consortium's research period for validating the usefulness of PXB mice ended, and CMHL's role in operating and managing the consortium consequently ended.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.